Ph.D., Vice President, Janssen R&D
Dr. Nicholas Dracopoli is Vice President, Head Oncology Biomarkers at Janssen R&D, Johnson & Johnson. In this role he is responsible for biomarker discovery, development and applications for oncology products. Previously, he was Vice President of Clinical Discovery Technologies at Bristol-Myers Squibb, and prior to that spent five years in the biotechnology industry at Sequana Therapeutics. Dr Dracopoli obtained his B.Sc. and Ph.D. degrees from the University of London, and completed post-doctoral fellowships at the Memorial Sloan-Kettering Cancer Center and the Massachusetts Institute of Technology (MIT). Subsequently, he served as an Assistant Director at the Whitehead/MIT Genome Center, and as a Section Chief at the National Center for Human Genome Research at the NIH before moving to the biotechnology industry. Dr Dracopoli has authored >70 scientific publications, and has extensive experience in the fields of genomics, molecular biology and cancer research.
cfDNA or CTCs: Which is Better?
Differential response to targeted therapies is driven by clonal selection of highly heterogeneous tumors during disease progression and treatment. Circulating Tumor Cells (CTC) and cfDNA permit access to tumor derived material without the need for invasive biopsies. The advantages and disadvantages of each template for liquid biopsies will be explored.